Athira Pharma announced multiple agreements to finance operations and secure global rights needed to advance oral lasofoxifene in metastatic breast cancer. The company signed a $90 million private placement with leading healthcare investors, paired with registration rights to provide resale liquidity. Athira also executed an exclusive license with Sermonix Pharmaceuticals for territories outside Asia and certain Middle Eastern countries and a direct exclusive license with Ligand Pharmaceuticals for oral lasofoxifene IP, aligning rights and economics for potential commercialization. As part of the license consideration, Athira will issue a pre-funded warrant to Sermonix and provide related registration rights. Management expects these actions to strengthen the balance sheet and accelerate clinical progress, including the ongoing Phase 3 ELAINE-3 study.

Agreement 1: Athira Pharma Signs Securities Purchase Agreement With Institutional Investors

• Agreement type: Private placement of common stock, pre-funded warrants, and common warrants
• Counterparty: Select institutional investors including Commodore Capital, TCGX and Perceptive Advisors
• Signed / Effective: Dec 18 2025 / Dec 23 2025
• Reason: Fund development of lasofoxifene and ATH-1105

Agreement 2: Athira Pharma Signs Registration Rights Agreement With PIPE Purchasers

• Agreement type: Registration rights agreement for PIPE resale
• Counterparty: PIPE Purchasers
• Signed / Effective: Dec 23 2025 / Dec 23 2025
• Reason: Provide resale liquidity to PIPE investors

Agreement 3: Athira Pharma Signs License Agreement With Sermonix Pharmaceuticals

• Agreement type: Exclusive license for oral lasofoxifene outside Asia and parts of Middle East
• Counterparty: Sermonix Pharmaceuticals
• Signed / Effective: Dec 18 2025 / Dec 18 2025
• Duration / Termination: Until no Licensed Products are developed or commercialized
• Reason: Acquire late-stage oncology asset and advance ELAINE-3

Agreement 4: Athira Pharma Signs License Agreement With Ligand Pharmaceuticals

• Agreement type: Exclusive license for oral lasofoxifene IP in licensed territory
• Counterparty: Ligand Pharmaceuticals
• Signed / Effective: Dec 18 2025 / Dec 18 2025
• Duration / Termination: So long as development or commercialization continues
• Reason: Align IP rights to enable development and commercialization

Agreement 5: Athira Pharma Signs Securities Purchase Agreement With Sermonix Pharmaceuticals

• Agreement type: Securities purchase agreement for pre-funded warrant issuance
• Counterparty: Sermonix Pharmaceuticals
• Signed / Effective: Dec 18 2025 / Dec 23 2025
• Reason: Provide equity consideration for the Sermonix license

Agreement 6: Athira Pharma Signs Registration Rights Agreement With Sermonix Pharmaceuticals

• Agreement type: Registration rights agreement for Sermonix resale
• Counterparty: Sermonix Pharmaceuticals
• Signed / Effective: Dec 23 2025 / Dec 23 2025
• Reason: Facilitate resale of warrant shares for Sermonix

Original SEC Filing: Athira Pharma, Inc. [ ATHA ] - 8-K - Dec. 18, 2025